Claims for Patent: 5,240,923

Summary for Patent: 5,240,923

Title:	Sulfonamides useful as carbonic anhydrase inhibitors
Abstract:	Sulfonamides and pharmaceutical compositions containing the compounds useful in controlling intraocular pressure are disclosed. Methods for controlling intraocular pressure through administration of the compositions are also disclosed.
Inventor(s):	Dean; Thomas R. (Weatherford, TX), Chen; Hwang-Hsing (Fort Worth, TX), May; Jesse A. (Fort Worth, TX)
Assignee:	Alcon Laboratories, Inc. (Fort Worth, TX)
Application Number:	07/775,313
Patent Claims:	1. A compound selected from the group consisting of: 3,4-Dihydro-2-(2-methoxy)ethyl-4-propylamino-2H- thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; 2-(2-Ethoxyethyl-)-4-ethylamino-3,4-dihydro-2H-thieno[3,2-e]-1,2-thiazine-6 -sulfonamide 1,1-dioxide; 2-(2-Ethoxy)ethyl-3,4-dihydro-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6 -sulfonamide 1,1-dioxide; 4-Ethylamino-3,4-dihydro-2-(3-methoxy)propyl-2H-thieno[3,2-e]-1,2-thiazine- 6-sulfonamide 1,1-dioxide; 3,4-Dihydro-2-(3-methoxy)propyl-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine -6-sulfonamide 1,1-dioxide; 3,4-Dihydro-2-[2-(methoxyethoxy)ethyl]-4-propylamino-2H-thieno[3,2-e]-1,2-t hiazine-6-syulfonamide 1,1-dioxide; Ethylamino-3,4-dihydro-2-[2-(methoxyethoxy)ethyl]-2H-thieno[3,2-e]-1,2-thi azine-6-sulfonamide 1,1-dioxide; 4-Ethylamino-3,4-dihydro-2-[3-(methoxyethoxy)propyl]-2H-thieno[3,2-e]-1,2-t hiazine-6-sulfonamide 1,1-dioxide; and 3,4-Dihydro-2-[3-(methoxyethoxy)propyl]-4-propylamino-2H-thieno[3,2-e]-1,2- thiazine-6-sulfonamide 1,1-dioxide. 2. The compound of claim 10 which is 3,4-Dihydro-2-(2-methoxy)ethyl-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine- 6-sulfonamide 1,1-dioxide. 3. The Compound of claim 1 which is 4-Ethylamino-3,4-dihydro-2-(3-methoxy)propyl-2H-thieno[3,2-e]-1,2-thiazine -6-sulfonamide -1,1-dioxide. 4. R-(+)-4-Ethylamino-3,4-di hydro-2-(2-methoxy)ethyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide. 5. R-(+)-3,4- Dihydro-2-(2-methoxy)ethyl-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-su lfonamide 1,1-dioxide. 6. A formulation for controlling intraocular pressure comprising a therapeutically effective amount of the compound of claim 1 in a pharmaceutically acceptable carrier. 7. The formulation of claim 6 wherein the compound concentration is between about 0.1 and 10% by weight. 8. A formulation for controlling intraocular pressure comprising a therapeutically effective amount of the compound of claim 4 in a pharmaceutically acceptable carrier. 9. The formulation of claim 8 wherein the compound concentration is between about 0.1 and 10% by weight. 10. The formulation of claim 9 wherein the concentration is between about 0.25 wt % and 5.0 wt %. 11. A formulation for controlling intraocular pressure comprising a therapeutically effective amount of the Compound of claim 5 in a pharmaceutically acceptable carrier. 12. The formulation of claim 11 wherein the compound concentration is between about 0.1 and 10% by weight. 13. The formulation of claim 12 wherein the concentration is between about 0.25 wt % and 5.0 wt %. 14. A method for controlling intraocular pressure which comprises topically administering to the affected eye a therapeutically effective amount of the compound of claim 1.